Calderdale Royal Hospital, Calderdale and Huddersfield NHS Foundation Trust, Halifax, United Kingdom.
Department of Infectious Disease Epidemiology, The London School of Hygiene and Tropical Medicine, London, United Kingdom.
PLoS One. 2020 Dec 31;15(12):e0244857. doi: 10.1371/journal.pone.0244857. eCollection 2020.
Continuous positive airway pressure (CPAP) ventilation may be used as a potential bridge to invasive mechanical ventilation (IMV), or as a ceiling-of-care for persistent hypoxaemia despite standard oxygen therapy, according to UK guidelines. We examined the association of mode of respiratory support and ceiling-of-care on mortality.
We conducted a retrospective cohort analysis of routinely collected de-identified data of adults with nasal/throat SARs-CoV-2 swab-positive results, at the Calderdale and Huddersfield NHS Foundation Trust between 10th March-19th April 2020 (outcomes determined on 22nd May).
Of 347 patients with SARs-CoV-2 swab-positive results, 294 (84.7%) patients admitted for Covid-19 were included in the study. Sixty-nine patients were trialled on CPAP, mostly delivered by face mask, either as an early ceiling of care instituted within 24 hours of admission (N = 19), or as a potential bridge to IMV (N = 44). Patients receiving a ceiling of care more than 24 hours after admission (N = 6) were excluded from the analysis. Two hundred and fifteen patients (73.1%) maximally received air/standard oxygen therapy, and 45 (15.3%) patients maximally received CPAP. Thirty-four patients (11.6%) required IMV, of which 24 had received prior CPAP. There were 138 patients with an early ceiling-of-care plan (pre-admission/within 24h). Overall, 103(35.0%) patients died and 191(65.0%) were alive at study end. Among all patients trialled on CPAP either as a potential bridge to IMV (N = 44) or as a ceiling-of-care (N = 19) mortality was 25% and 84%, respectively. Overall, there was strong evidence for higher mortality among patients who required CPAP or IMV, compared to those who required only air/oxygen (aOR 5.24 95%CI: 1.38, 19.81 and aOR 46.47 95%CI: 7.52, 287.08, respectively; p<0.001), and among patients with early ceiling-of-care compared to those without a ceiling (aOR 41.81 95%CI: 8.28, 211.17; p<0.001). Among patients without a ceiling of care (N = 137), 10 patients required prompt intubation following failed oxygen therapy, but 44 patients received CPAP. CPAP failure, defined as death (N = 1) or intubation (N = 24), occurred in 57% (N = 25) of patients. But in total, 75% (N = 33) of those started on CPAP with no ceiling of care recovered to discharge-19 without the need for IMV, and 14 following IMV.
Our data suggest that among patients with no ceiling-of-care, an initial trial of CPAP as a potential bridge to IMV offers a favourable therapeutic alternative to early intubation. In contrast, among patients with a ceiling-of care, CPAP seems to offer little additional survival benefit beyond oxygen therapy alone. Information on ceilings of respiratory support is vital to interpreting mortality from Covid-19.
Sample size relatively small.Study sample representative of hospitalised Covid-19 patients in UK.Previously unreported data on role of ceilings-of-care in hospitalised Covid-19 patients.Novel data on use of CPAP separated by indication.
根据英国指南,持续气道正压通气(CPAP)通气可作为侵入性机械通气(IMV)的潜在桥梁,也可作为标准氧疗后持续低氧血症的治疗上限。我们研究了呼吸支持方式和治疗上限与死亡率之间的关系。
我们对 2020 年 3 月 10 日至 4 月 19 日在 Calderdale 和 Huddersfield NHS 基金会信托基金接受鼻/咽 SARS-CoV-2 拭子检测阳性结果的成年人进行了回顾性队列分析(结果于 5 月 22 日确定)。
在 347 名 SARS-CoV-2 拭子检测阳性的患者中,294 名(84.7%)因 COVID-19 住院的患者被纳入研究。69 名患者接受 CPAP 治疗,主要通过面罩提供,要么在入院后 24 小时内作为早期治疗上限(N=19),要么作为 IMV 的潜在桥接(N=44)。在入院后 24 小时以上接受治疗上限的患者(N=6)被排除在分析之外。215 名患者(73.1%)最大程度地接受了空气/标准氧疗,45 名患者(15.3%)最大程度地接受了 CPAP。34 名患者(11.6%)需要 IMV,其中 24 名患者在之前接受过 CPAP。有 138 名患者有早期治疗上限计划(入院前/24 小时内)。总的来说,103 名(35.0%)患者死亡,191 名(65.0%)患者在研究结束时存活。在所有接受 CPAP 治疗的患者中,无论是作为潜在的 IMV 桥接(N=44)还是作为治疗上限(N=19),死亡率分别为 25%和 84%。总的来说,与仅需要空气/氧气的患者相比,需要 CPAP 或 IMV 的患者死亡率更高(比值比 5.24,95%置信区间:1.38,19.81 和比值比 46.47,95%置信区间:7.52,287.08;均 P<0.001),与没有治疗上限的患者相比,早期有治疗上限的患者死亡率更高(比值比 41.81,95%置信区间:8.28,211.17;P<0.001)。在没有治疗上限的患者中(N=137),10 名患者在氧疗失败后需要立即插管,但 44 名患者接受了 CPAP。CPAP 失败(死亡 N=1,插管 N=24)发生在 57%(N=25)的患者中。但总的来说,在没有治疗上限的患者中,75%(N=33)开始接受 CPAP 治疗的患者康复出院-19 名患者无需接受 IMV,14 名患者在接受 IMV 后康复出院。
我们的数据表明,在没有治疗上限的患者中,CPAP 作为潜在的 IMV 桥接的初始尝试,为早期插管提供了一种有利的治疗替代方案。相比之下,在有治疗上限的患者中,CPAP 似乎除了单独吸氧之外,对生存没有额外的益处。关于呼吸支持治疗上限的信息对于解释 COVID-19 的死亡率至关重要。
样本量相对较小。研究样本代表了英国住院 COVID-19 患者。以前未报告过 CPAP 在住院 COVID-19 患者中的作用上限数据。关于 CPAP 用途的新数据按指示分开。